



ASX ANNOUNCEMENT

4 December 2014

Cynata to Present at Major International Stem Cell Conference

Melbourne, Australia; 4 December 2014: Stem cell and regenerative medicine company, Cynata Therapeutics Ltd (ASX: CYP), announced today that the Company has been invited to present at the RegMed Capital Conference (RMCC) being held this week as part of the World Stem Cell Summit in Texas. Approximately 1,200 investors, industry executives, scientists, physicians and venture capitalists from some 40 countries are expected to attend the three-day global conference, commencing December 3rd.

Media contacts: Dr Ross Macdonald, CEO: Tel: 0412 119343; email ross.macdonald@cynata.com
Dr Stewart Washer, Executive Chairman: Tel: 0418 288212; email stewart.washer@cynata.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.